Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
SchizophreniaSchizoaffective DisorderBipolar Affective Disorder
Interventions
DRUG

Placebo

Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.

DRUG

Melatonin

Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.

Trial Locations (1)

2600

Center for Neuropsychiatric Schizophrenia Research (CNSR)/Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), University of Copenhagen, Mental Health Centre Glostrup, Mental Health Services - Capital Region of Denmark, Glostrup Municipality

All Listed Sponsors
collaborator

Glostrup University Hospital, Copenhagen

OTHER

collaborator

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

lead

Lone Baandrup

OTHER

NCT01431092 - Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter